Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28846692 | 0.84 | SCD (0.54) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL6512552 | 0.82 | PTGS2 (0.69) | PTGS2 | |
| SCHEMBL5052625 | 0.81 | LTA4H (0.50) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL7058218 | 0.81 | CA2 (0.51) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL13742923 | 0.81 | CA2 (0.61) | PTGS2CA12CA1CA2MMP2 | |
| SCHEMBL4804285 | 0.81 | CA2 (0.55) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL4796613 | 0.81 | CA2 (0.51) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL6513622 | 0.81 | PTGS2 (0.67) | SCDPTGS2 | |
| SCHEMBL6512795 | 0.81 | PTGS2 (0.45) | SCDPTGS2CA12CA1CA2 | |
| SCHEMBL6512790 | 0.81 | PTGS2 (0.45) | SCDPTGS2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106957431-B | Process for producing polyarylene sulfide | 财团法人工业技术研究院 | 2019-06-07 | — | — | CN | claimed |
| CN-106957431-A | Process for producing polyarylene sulfide | 财团法人工业技术研究院 | 2017-07-18 | — | — | CN | claimed |
| CN-106957431-B | Process for producing polyarylene sulfide | 财团法人工业技术研究院 | 2019-06-07 | — | — | CN | disclosed |
| CN-107428938-A | Polyarylene sulfide resin and method for producing same, and poly (arylsulfonium salt) and method for producing same | DIC株式会社 | 2017-12-01 | — | — | CN | disclosed |
| CN-105492499-B | Polyarylene sulfide resin, process for producing the same, and molded article | DIC株式会社 | 2017-08-08 | — | — | CN | disclosed |
| CN-106986803-A | Cationic sulfoxide intermediate, polyarylene sulfide monomer and preparation method of polyarylene sulfide | 财团法人工业技术研究院 | 2017-07-28 | — | — | CN | disclosed |
| CN-106957431-A | Process for producing polyarylene sulfide | 财团法人工业技术研究院 | 2017-07-18 | — | — | CN | disclosed |
| CN-105492499-A | Polyarylene sulfide resin, process for producing the same, and molded article | DAINIPPON INK & CHEMICALS | 2016-04-13 | — | — | CN | disclosed |
| US-8476225-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20030013744-A1 | 3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013744-A1 | 3,4-diaryl thiophenes and analogs thereof having use as anti-inflammatory agents | NR3C1, FPR1, IL1B | SCD 829/4885PTGS2 151/4885CA12 4657/4885 |
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE3B | SCD 2921/4885PTGS2 526/4885CA12 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.